NITROSAMINAS EM MEDICAMENTOS: RISCOS CARCINOGÊNICOS E RESPOSTAS REGULATÓRIAS INTERNACIONAIS — UMA REVISÃO INTEGRATIVA

The control of N-nitrosamines (NAs) in medicines became one of the main regulatory challenges for the pharmaceutical industry after 2018, when the detection of N-nitrosodimethylamine in valsartan triggered mass recalls and a thorough revision of global health guidelines. This study sought to synthesize the scientific literature on regulatory advances and challenges related to NAs, characterizing the formation of these impurities, their carcinogenic mechanisms, the therapeutic classes affected and the normative responses of international regulatory agencies. An integrative review was conducted with searches in the PubMed, LILACS and Web of Science databases, using the terms N-nitrosamine, NDMA, NDEA, NMBA, regulatory, guideline, FDA, EMA, ICH, ANVISA, drug, pharmaceutical and active pharmaceutical ingredient, combined with the Boolean operators AND and OR, covering the period from 2018 to 2026. Nine scientific studies were selected, including systematic and narrative reviews, regulatory commentaries and toxicological studies, in addition to six normative documents retrieved manually from FDA, EMA, ANVISA, Health Canada and ICH. An in silico structural analysis of more than 12,000 active pharmaceutical ingredients (APIs) found that 40.4% have characteristics of potential NA precursors, bearing in mind that the structural presence of precursors does not guarantee the actual formation of these impurities. International regulatory responses advanced from emergency measures to structured frameworks based on acceptable intake limits, stepwise risk assessment and high-sensitivity analytical methods. The balance between regulatory stringency and continuity of supply remains a challenge, requiring international cooperation, generation of toxicological data and harmonization of the limits applicable to nitrosamine drug substance-related impurities (NDSRIs).

Authors

Institutions

Publication Details

Journal
RECIMA21 - Revista Científica Multidisciplinar
Published
2026-11-12
DOI
https://doi.org/10.47820/recima21.v7i11.9484
Primary Topic
Pharmaceutical Quality and Counterfeiting
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

NITROSAMINAS EM MEDICAMENTOS: RISCOS CARCINOGÊNICOS E RESPOSTAS REGULATÓRIAS INTERNACIONAIS — UMA REVISÃO INTEGRATIVA

Danielle Cristine Almeida Silva de Santana, Fernando José Malagueño de Santana, Yasmin Carvalho da Rocha Wanderley, Manoel Lucas da Silva et al.
RECIMA21 - Revista Científica Multidisciplinar
Pharmaceutical Quality and Counterfeiting
article

NITROSAMINAS EM MEDICAMENTOS: RISCOS CARCINOGÊNICOS E RESPOSTAS REGULATÓRIAS INTERNACIONAIS — UMA REVISÃO INTEGRATIVA

Danielle Cristine Almeida Silva de Santana, Fernando José Malagueño de Santana, Yasmin Carvalho da Rocha Wanderley, Manoel Lucas da Silva, Thatyana de Souza Silva
article en

Abstract

The control of N-nitrosamines (NAs) in medicines became one of the main regulatory challenges for the pharmaceutical industry after 2018, when the detection of N-nitrosodimethylamine in valsartan triggered mass recalls and a thorough revision of global health guidelines. This study sought to synthesize the scientific literature on regulatory advances and challenges related to NAs, characterizing the formation of these impurities, their carcinogenic mechanisms, the therapeutic classes affected and the normative responses of international regulatory agencies. An integrative review was conducted with searches in the PubMed, LILACS and Web of Science databases, using the terms N-nitrosamine, NDMA, NDEA, NMBA, regulatory, guideline, FDA, EMA, ICH, ANVISA, drug, pharmaceutical and active pharmaceutical ingredient, combined with the Boolean operators AND and OR, covering the period from 2018 to 2026. Nine scientific studies were selected, including systematic and narrative reviews, regulatory commentaries and toxicological studies, in addition to six normative documents retrieved manually from FDA, EMA, ANVISA, Health Canada and ICH. An in silico structural analysis of more than 12,000 active pharmaceutical ingredients (APIs) found that 40.4% have characteristics of potential NA precursors, bearing in mind that the structural presence of precursors does not guarantee the actual formation of these impurities. International regulatory responses advanced from emergency measures to structured frameworks based on acceptable intake limits, stepwise risk assessment and high-sensitivity analytical methods. The balance between regulatory stringency and continuity of supply remains a challenge, requiring international cooperation, generation of toxicological data and harmonization of the limits applicable to nitrosamine drug substance-related impurities (NDSRIs).

RECIMA21 - Revista Científica MultidisciplinarVol. 7(11)
Universidade de São Paulo (BR), Universidade Federal de Pernambuco (BR), Instituto Federal de Educação, Ciência e Tecnologia de Pernambuco (BR)
Good health and well-being
Pharmaceutical Quality and Counterfeiting
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon